ASIDE FROM THOSE INCORPORATED IN THE GUIDELINES OF ONCOLOGY PRACTICE
1.EGFR
2.ALK
Now we are hearing about the following
1.ROS-1
2.MEK-1
3.RET
4.BRAF
5.HER-2
6.PI3KCA
7.KRAS
8.PD-1,2
9.ERCC1
10.BRCA-1 mRNA
11 P53
What about the therapeutic roles of :
GSTM-1 and GSTT1,FAK, Wnt, Notch, p16,
HIF and VGEF and the CYP1A1,P ?
A blog about research, awareness, prevention, treatment and survivorship of Breast Cancer and all cancers, including targeted scientific research and a grassroots approach to increase screening for cancer, especially in the low income and under-insured population of El Paso, Texas, with a view to expand this new health care model to many other 'minority' populations across the United States and beyond
Showing posts with label VGEF. Show all posts
Showing posts with label VGEF. Show all posts
Thursday, November 14, 2013
NEW GENES ARE BEING INCLUDED IN THE CLINICAL THERAPY OF LUNG CANCERS!
Labels:
16,
BRCA-1 mRNA,
crbcm,
CYP1A1,
ERCC1,
FAK,
GSTM-1,
GSTT1,
HIF,
kankonde,
KRAS,
lung cancer,
notch,
P53,
PI3KCA,
VGEF,
Wnt
Subscribe to:
Posts (Atom)